header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FIG-140522-6
Nissim et al., 2014 - Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth. Developmental Cell   28(4):423-437 Full text @ Dev. Cell
ADDITIONAL FIGURES
EXPRESSION / LABELING:
Genes:
Fish:
Conditions:
Knockdown Reagents:
Anatomical Term:
Stage: Protruding-mouth
PHENOTYPE:
Fish:
Conditions:
Knockdown Reagents:
Observed In:
Stage: Protruding-mouth

Fig. 1 PGE2 Affects Embryonic Liver Outgrowth (A) In situ hybridization for transferrin, a liver-specific marker, reveals that embryonic liver size is regulated by PGE2. Exposure to dmPGE2 from 48 to 80 hpf dramatically increases embryonic liver size (51.4% embryos with an enlarged liver; n = 18/35), whereas exposure to Indo decreases embryonic liver size (76.5% embryos with a smaller liver; n = 26/34). Left lateral view; row below is magnified view. (B) FACS quantification of GFP+ liver cells in lfabp:GFP embryos at 72 hpf following exposure to dmPGE2 or Indo. dmPGE2 increases the relative number of liver cells, whereas Indo decreases the relative number of liver cells. (Data are represented as mean ± SEM; ***significant across treatment groups, ANOVA, p = 0.0009.) (C) Confocal microscopy visualization of the liver in lfabp:GFP embryos at 72 hpf following exposure to dmPGE2 or Indo. Exposure to dmPGE2 from 48 to 72 hpf enlarges the developing liver, whereas exposure to Indo severely abrogates liver development. Left lateral view. (Data are represented as mean ± SEM; n = 5 per treatment.)

Gene Expression Details
Gene Antibody Fish Conditions Stage Anatomy Assay
EGFP as3Tg control Protruding-mouth liver IFL
as3Tg chemical treatment: prostaglandin E2 Protruding-mouth liver IFL
as3Tg chemical treatment: indometacin Protruding-mouth liver IFL
as3Tg + MO1-ptger2a + MO2-ptger2a control Protruding-mouth liver IFL
as3Tg + MO1-ptger2a + MO2-ptger2a chemical treatment: prostaglandin E2 Protruding-mouth liver IFL
as3Tg + MO1-ptger4a + MO2-ptger4a control Protruding-mouth liver IFL
as3Tg + MO1-ptger4a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth liver IFL
as3Tg + MO1-ptgs1 + MO2-ptgs1 control Protruding-mouth liver IFL
as3Tg + MO1-ptgs1 + MO2-ptgs1 chemical treatment: prostaglandin E2 Protruding-mouth liver IFL
as3Tg + MO1-ptgs2a + MO2-ptgs2a control Protruding-mouth liver IFL
as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth liver IFL
tfa WT control Protruding-mouth liver ISH
WT chemical treatment: prostaglandin E2 Protruding-mouth liver ISH
WT chemical treatment: indometacin Protruding-mouth liver ISH
Antibody Labeling Details No data available
Phenotype Details
Fish Conditions Stage Phenotype
WT chemical treatment: prostaglandin E2 Protruding-mouth liver tfa expression increased distribution, abnormal
Protruding-mouth liver increased size, abnormal
WT chemical treatment: indometacin Protruding-mouth liver tfa expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
as3Tg chemical treatment: prostaglandin E2 Protruding-mouth liver EGFP expression increased distribution, abnormal
Protruding-mouth liver increased size, abnormal
Protruding-mouth liver cell increased amount, abnormal
as3Tg chemical treatment: indometacin Protruding-mouth liver EGFP expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
Protruding-mouth liver cell decreased amount, abnormal
as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a control Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptger2a + MO1-ptger4a + MO2-ptger2a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptger2a + MO2-ptger2a control Protruding-mouth liver EGFP expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptger2a + MO2-ptger2a chemical treatment: prostaglandin E2 Protruding-mouth liver EGFP expression amount, ameliorated
Protruding-mouth liver size, ameliorated
as3Tg + MO1-ptger4a + MO2-ptger4a control Protruding-mouth liver EGFP expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptger4a + MO2-ptger4a chemical treatment: prostaglandin E2 Protruding-mouth liver EGFP expression amount, ameliorated
Protruding-mouth liver size, ameliorated
as3Tg + MO1-ptgs1 + MO2-ptgs1 control Protruding-mouth liver EGFP expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptgs1 + MO2-ptgs1 chemical treatment: prostaglandin E2 Protruding-mouth liver EGFP expression amount, ameliorated
Protruding-mouth liver size, ameliorated
as3Tg + MO1-ptgs2a + MO2-ptgs2a control Protruding-mouth liver EGFP expression decreased distribution, abnormal
Protruding-mouth liver decreased size, abnormal
as3Tg + MO1-ptgs2a + MO2-ptgs2a chemical treatment: prostaglandin E2 Protruding-mouth liver EGFP expression amount, ameliorated
Protruding-mouth liver size, ameliorated
Acknowledgments:
ZFIN wishes to thank the journal Developmental Cell for permission to reproduce figures from this article. Please note that this material may be protected by copyright.

Reprinted from Developmental Cell, 28(4), Nissim, S., Sherwood, R.I., Wucherpfennig, J., Saunders, D., Harris, J.M., Esain, V., Carroll, K.J., Frechette, G.M., Kim, A.J., Hwang, K.L., Cutting, C.C., Elledge, S., North, T.E., and Goessling, W., Prostaglandin E2 regulates liver versus pancreas cell-fate decisions and endodermal outgrowth, 423-437, Copyright (2014) with permission from Elsevier. Full text @ Dev. Cell